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Abstract Technical advances in generating and pheno-
typing cardiomyocytes from human pluripotent stem cells
(hPSC-CMs) are now driving their wider acceptance as
in vitro models to understand human heart disease and
discover therapeutic targets that may lead to new com-
pounds for clinical use. Current literature clearly shows
that hPSC-CMs recapitulate many molecular, cellular, and
functional aspects of human heart pathophysiology and
their responses to cardioactive drugs. Here, we provide a
comprehensive overview of hPSC-CMs models that have
been described to date and highlight their most recent and
remarkable contributions to research on cardiovascular
diseases and disorders with cardiac traits. We conclude
discussing immediate challenges, limitations, and emerg-
ing solutions.
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hESCs Human embryonic stem cells
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RBM20 RNA-binding motif protein 20
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RMP Resting membrane potential









T2DM Type-2 diabetes mellitus
Vmax Maximum upstroke velocity
Introduction
Human embryonic stem cells, derived from the early human
embryos, and human-induced pluripotent stem cells, derived
by reprogramming somatic cells (hESCs and hiPSCs,
respectively, and collectively called hPSCs) can self-renew
and differentiate into all cell types of the human body,
including cardiomyocytes [1–3]. They have potential
applications in regenerative medicine but are also becoming
a useful tool in cardiovascular research. Most particularly,
they offer new opportunities to develop in vitro models of
human cardiac development and cardiovascular diseases, as
they are able to capture much of the normal and pathological
physiology of the human heart, including aspects of con-
genital defects. In addition, hPSC-derived cardiomyocytes
(hPSC-CMs) may be used in cardiac safety pharmacology,
drug screening, and drug discovery, to predict the effects of
candidate drugs and new compounds and to identify key
target pathways in disease. Whilst hESCs can now readily
be engineered to carry specific disease mutations, the
derivation of hiPSCs from virtually any patient of interest
offers some advantages over hESCs for disease modeling,
since hiPSCs incorporate individual complex genetic back-
grounds of the patients from which they were originated. For
this reason, expectations are high on their contribution to
precision medicine where the goal is to prevent disease
development and find personalized treatments that take
genetic variability of patients into account [4].
In this review, we provide comprehensive coverage of
hPSC models of human heart disease.
Generation of hiPSCs and hESCs for cardiac
disease modeling
The need for more robust cell models for human disease,
including cardiovascular disorders, has led to increasing
interest in hPSCs.
hESCs were the first human pluripotent stem cells
described. They were derived from the inner cell mass of
blastocyst-stage embryos in 1998 by Thomson [1]. These
cells could differentiate toward cell lineages of all three
germ layers yet to be maintained in a state of self-renewal
indefinitely in their undifferentiated state. Multiple hESC
lines have been used successfully for studying genetic
disorders most often through specific gene knockdown or
deletion using homologous recombination [5] or lentiviral
transduction [6]. Furthermore, in the case of some poten-
tially fatal of untreatable conditions, hESCs have also been
derived from preimplantation embryos genetically diag-
nosed as defective by single blastomere sampling during
Preimplantation Genetic Diagnosis (PGD). Disorders that
have been studied using PGD-hESC include a number of
severe congenital disorders such as fragile X syndrome [7],
Turner syndrome [8], and trisomy 21 [9]. However, hESC
lines to investigate multifactorial and complex diseases
may not be available through PGD, because they may not
be considered sufficiently severe [10], as is the case for
many cardiac diseases. Thus, even though hESCs are useful
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when there is pre-existing knowledge on the specific
mutations causing the disease and the mutations can be
introduced into an otherwise healthy line, hiPSCs are
preferred where the entire genetic background is relevant.
The use of patient somatic cells to derive hiPSCs is also
preferable in some countries, since it circumvents ethical
issues that surround the destruction of human embryos for
research purposes. The advent of hiPSCs has also super-
seded efforts to derive cloned embryos by somatic cell
nuclear transfer and isolate individual hESC lines from
them [2, 11, 12]. Many methods have now been described
that allow somatic cell reprogramming [13]. The first and
still among the most efficient methods described overex-
press the reprogramming factors c-MYC, SOX2, KLF4,
and OCT3/4 after retroviral or lentiviral transduction of
dermal fibroblasts. This results in the integration of
reprogramming genes into the genome and subsequent
reactivation of the endogenous counterparts [11, 14].
Alternative non-integrating reprogramming methods are
now more widely used and include the use of Sendai
viruses [15], plasmids [16], and modified RNA [17]. Small
molecules have also been used but have relatively lower
efficiencies [18]. Somatic cell sources currently used for
reprogramming not only include the original dermal
fibroblasts isolated from skin biopsies, but also blood cells
[19], keratinocytes from plucked hair [20], and exfoliated
renal tubular epithelial cells obtained from urine [21].
Many patient-specific lines have been described that are
suitable for cardiovascular disease modeling and are
proving of particular value for studying disorders of
unknown or complex genetic origin, as will be discussed in
this review.
Differentiation into cardiomyocytes
In vitro differentiation of hPSCs into cardiomyocytes
mimics the sequential stages of embryonic cardiac
development [22]. In the vertebrate embryo, the heart is
one of the first organs to develop; after gastrulation,
anterior migrating mesodermal cells intercalate between
the ectoderm and the endoderm germ layers in the prim-
itive streak to start generating the heart [23, 24]. Cardiac
progenitor cells derive from two small tracts of epiblast
cells of the developing primitive streak and take residence
in the lateral plate mesoderm [25]. Signals from the sur-
rounding tissues, such as growth factors of the WNT,
BMP, and TGF-b families, are critical to promote the
specification of myocardial fate. Accordingly, many of
the successful protocols developed to induce cardiomyo-
genesis in hPSCs are based on activating and inhibiting
these signaling pathways. As an example, stimulation of
extraembryonic ectoderm via BMP signaling (by BMP4)
and posterior primitive streak via WNT signaling (by
CHIR99201) during the first 24 h of differentiation pro-
motes the exit from self-renewal and the induction of
cardiac mesoderm [26]. Moreover, inhibitors of WNT
signaling, such as IWR-1, IWP-3, and XAV939, have
been shown to induce cardiogenesis when added after
mesoderm formation [27–29], while SB-431542, an
inhibitor of the TGF-b pathway, promotes cardiogenesis
when its addition occurs after mesoderm specification
[30]. Current methods for cardiac differentiation of hPSCs
rely on three different approaches that are summarized in
Table 1, embryoid body formation, co-cultures, and
monolayer culture [22].
Functional cardiomyocytes can be generated from
hPSCs as three-dimensional spheroid-like aggregates ter-
med embryoid bodies (EBs), referring to their similarity
with the early post-implantation embryos. Protocols to
form EBs were originally developed using fetal bovine
serum supplemented culture medium, but a variety of
serum-free, defined media formulations are now available.
Methods to form EBs from hPSCs range from an enzy-
matic partial dissociation of hPSC colonies, and to precise
control of cell number and size by forced aggregation in
microwells, to microwells in which hPSC colonies are first
expanded to a defined size, to micropatterned substrates
[22].
Alternatively, the early studies also used inductive co-
culture of mechanically passaged hESCs with visceral
endodermal-like END2 cells derived from mouse P19
embryonal carcinoma cells [31]. Notably, visceral endo-
derm plays a key role in the induction of cardiogenic
precursor cells in development.
For ease of use though, monolayer differentiation
protocols have been preferred. Benefits compared to the
EB and co-culture systems include higher efficiencies and
easy monitoring of outcome. Refinements over the last
decade now support the generation of differentiated cell
populations containing 85% cardiomyocytes; multiple
methods have been described in which cardiomyocytes
can be enriched to 95% using, for example, selection in
sodium (Na?) lactate containing medium [32–34] or on
the basis of cell surface markers like SIRPA and VCAM1
[28, 35].
Cardiomyocytes derived under all these culture condi-
tions beat spontaneously, express sarcomeric proteins and
ion channels, and exhibit cardiac-type action potentials
(APs) and calcium (Ca2?) transients. Furthermore, they
show similar functional properties to the cardiomyocytes in
the developing heart, such as comparable dose-dependent
response to cardiac drugs in terms of beating frequency and
contractility, b-adrenoreceptor responses, action potential
(AP) morphologies, and excitation–contraction coupling
mechanisms [36]. Although opportunities still remain for
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improvement of reproducibility in cardiac differentiation
between individual hPSC lines, reduction in the cost of
reagents and in batch-to-batch variability, and of the yield
and purity of required cardiomyocyte types, several pro-
tocols now support robust cardiac differentiation and some
of these are available commercially as kits.
Characterization of cardiomyocyte phenotype
The use of hPSC-CMs as a platform to model cardiovas-
cular disorders requires their rigorous molecular and
functional characterization. To maximize their potential
applications in cardiovascular medicine, a qualitative
comparison with adult (or fetal) primary human car-
diomyocytes is advisable. Parameters used to characterize
the cardiomyocyte phenotype are listed in Table 2 and
include size and morphology, sarcomere structure, elec-
trophysiological properties, Ca2? handling and contractile
force, responses to b-adrenergic stimulation, mitochondrial
function and metabolic profile, and conduction velocity.
Size and morphology
In the adult heart, cardiomyocytes are elongated and rod
shaped, and *65% of them are mononucleated and this
percentage does not change significantly throughout life
[37, 38]. Furthermore, adult cardiomyocytes align longi-
tudinally in the heart and are connected by intercalated
discs that facilitate the electrical conduction and muscle
contraction [39]. To date, despite the high differentiation
efficiencies now achievable, hPSC-CMs remain small in
size and round in shape [40] suggesting an immature or
fetal phenotype. Several strategies have been used to
mature hPSC-CMs. These include prolonged time in
culture ([50 days), where hPSC-CMs become more
elongated and less rounded [40] and advanced engineer-
ing approaches such as 3D platforms, either as
‘‘biowires’’, or engineered heart tissues (EHTs), which
allows the generation of hiPSC-CMs with improved
ultrastructural and electrophysiological properties
[41, 42]. Examples of improved ultrastructural properties
included cardiomyocyte anisotropy with Z bands
Table 1 Methods for differentiating hPSCs into cardiomyocytes (modified from [34])
Differentiation Culture conditions Limits Efficiencya (%) References
EBs Serum-based media Low efficiency
Serum media
5–15 [3]
RPMI ? B27 supplement
ActivinA ? BMP4
Medium efficiency




RPMI ? B27 supplement
Small molecules
Chemical undefined ‘‘B27’’ 90 [233]





Requirement for mouse feeder cells
35 [22]
Monolayer culture RPMI ? B27 supplement
ActivinA ? BMP4
Low efficiency
Batch-to-batch variability of growth factors
Chemically undefined ‘‘B27’’
35 [234]
RPMI ? B27 supplement
Matrigel Sandwich
ActivinA ? BMP4
Batch-to-batch variability of Matrigel and growth factors
Chemically undefined ‘‘B27’’
90 [235]
RPMI ? B27 supplement
Small molecules
Chemically undefined ‘‘B27’’ 90 [236]





ActivinA ? BMP4 Medium efficiency
Batch-to-batch variability of growth factors
50 [237]
a Efficiency was calculated from flow cytometry data as the number of cells positive for cardiac troponin T (cTnT), MLC-2a, and MLC-2v, by
immunostaining for MHC-b or by determining the percentage of EBs containing contracting areas
3714 E. Giacomelli et al.
123
frequently visible and aligned, pronounced presence of H
zones and I bands, and scattered presence of T-tubule-like
structures [41, 42]. These methods as well as other mat-
uration strategies are summarized in the ‘‘Conclusions’’
section of this review.
Sarcomere structure
Human adult cardiomyocytes are characterized by organized
and aligned sarcomeres [38], the smallest contractile units of
striated muscles. Sarcomeres are composed of contractile
proteins, including actin and myosin, which generate the
force of contraction, and thin filament proteins, which
calibrate the force generated by contractile proteins. In the
adult ventricle, the b isoform of the protein Myosin Heavy
Chain (MHC-b), encoded by the gene MYH7, is predomi-
nant compared to the atrial a isoform MHC-a, encoded by
MYH6 [43]; in addition, the isoform Myosin Light Chain 2v
(MLC-2v), encoded by the gene MYL2, is predominant
compared to the MLC-2a, encoded by MYL7, which is
instead the primary human atrial isoform. Similarly, a
genetic switch between the troponin I fetal (TNNI1) and
adult isoforms (TNNI3) in the human heart characterizes the
transition from fetal to post-natal development [44].
Sarcomeres in hPSC-CMs are less organized than in
adult cardiomyocytes, and MHC-a and MLC-2a are
Table 2 Key features used to characterize the human cardiomyocyte phenotype
Features Measured parameters Human adult cardiomyocyte











MYH7 predominant isoform in the ventricle
MYL7 predominant isoform in the atrium
Electrophysiological
properties
AP (APA, RMP, Vmax, APD)
Ion current densities and gating properties (INa,
ICaL, ICaT, Ito, IKur, IKr, IKs, IK1, IK,Ach, IK,ATP, If)
Typical atrial, ventricular, pacemaker, and Purkinje AP
shapes [238, 239]
Distinct ion current densities and function in atrial,
ventricular, pacemaker, and Purkinje cardiomyocytes
[238, 239]




Ca2? sparks and Ca2? waves
Efficient Ca2? transient induction by Ca2? influx through
L-type Ca2? channels (Ca2?-induced Ca2?-release) [52]
Force of contraction: 10–50 mN/mm2 (ventricular myocytes)
[240]
Positive force-frequency relationship (Bowditch
phenomenon) [241]


















Mitochondria occupies one-third of the total volume of CMs
ATP production occurs mainly through oxidative
metabolism (predominantly fatty acids)
Conduction velocity Conduction velocity maps
Expression level of ion channels and gap junction
proteins
Localization, density, and composition of gap
junction proteins
Generation of the electrical signal through Na? channels and
propagation through gap junctions
Localization of gap junction proteins at cell borders
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generally highly expressed, while MHC-b and MLC-2v
display relatively low level of expression [45]. In addition,
the TNNI1:TNNI3 protein isoform ratio reflects a fetal
stage, even after long-term culture [46]. This is partly due
to hPSC-CMs being more similar to fetal cardiomyocytes
but also to the heterogeneous nature of the hPSC-CMs
population, which consists on a mixture of ventricular-,
atrial-, and nodal-like cells. Recent engineering approaches
have attempted to improve sarcomere organization and
myofibril alignment in hPSC-CMs, to allow study of their
structural and contractile properties, such as actin–myosin
cross-bridge cycling, myofibril tension, and kinetics of
activation and relaxation. Examples include the work of
Salick and colleagues in which hESC-CMs were seeded
onto controlled two-dimensional micropatterned rectangles
made with high-resolution photolithography and micro-
contact printing [47], and the work of Pioner and
colleagues in which hiPSC-CMs were seeded on nano-
grooved surfaces and cultured long term (80–100 days)
[48]. Importantly, the latter study demonstrated that
myofibril tension and kinetics were similar between long-
term cultures of hiPSC-CMs and second trimester human
fetal ventricular cardiomyocytes. Importantly, the fetal
sarcomeric properties of hPSC-CMs may represent an
obstacle to faithfully recapitulating cardiomyopathy-asso-
ciated phenotypes that are linked to sarcomere protein
mutations. For example, the force of contraction was
decreased in hiPSC-CMs with MYBPC3 mutations com-
pared with wild-type cells, while hypertrophic
cardiomyopathy (HCM) due to sarcomeric mutations is
usually associated with hypercontractility [49, 50].
Electrophysiological properties
Electrophysiological properties of adult cardiomyocytes
can be described by their AP profile, which is widely
considered specific for each cardiomyocyte subtype (atrial,
ventricular, pacemaker, and Purkinje). However, indepen-
dent of subtype, AP always starts with a rapid influx of
Na? as a rapid depolarizing current (INa), termed ‘‘AP
upstroke’’ (phase 0). Afterwards, phase 1 of the AP is
characterized by a transient repolarizing current (Ito1) of
efflux of potassium (K?), followed by the inward Ca2?
current (ICaL) through the L-type depolarization-activated
Ca2? channels, which is called the plateau phase of the AP
(phase 2). Next, two K? currents (Iks and Ikr) drive the
repolarizing phase 3 of the AP. Hence, in adult atrial and
ventricular cardiomyocytes, the presence of a rectifying K?
current (Ik1) stabilizes the resting membrane potential
(RMP) at -85 mV; this is termed phase 4 of the AP.
hPSC-CMs are more depolarized compared to adult
cardiomyocytes: RMP is less negative (-50/-60 mV),
Na? channels are fewer, and phase 0 of the AP is slow. In
addition, hPSC-CMs exhibit spontaneous contractile
activity, due to the absence or very low expression of Ik1,
and the presence of a funny current (If), which is a pace-
maker Na?/K? hyperpolarizing current [51, 52].
Despite the differences with adult cardiomyocytes (re-
viewed in [53] and [54]), hPSC-CMs offer the opportunity
to study some developmental- and disease-relevant cardiac
properties. As an example, arrhythmogenic diseases of the
heart have successfully been recapitulated using patient
hiPSC-CMs, displaying significant AP changes, such as AP
prolongation in the long-QT syndrome [55]. In addition, in
2013, the US Food and Drug Administration (FDA) chose
hiPSC-CMs as cell type of choice for testing cardiac effects
of novel compounds [51].
Ca21 handling and contractile force (excitation–
contraction coupling)
The process termed ‘‘excitation–contraction coupling’’
(ECC) consists of the repeated contraction and relaxation
of the chambers of the heart, in which Ca2? is, perhaps, the
most important ion involved. Ca2? that enters the cell
during the plateau phase of the AP enhances Ca2? release
from the sarcoplasmic reticulum (SR) through ryanodine
receptor-2 (RYR2) channels. This causes an increase in
intracellular Ca2?, which binds to the myofilament protein
troponin C, activating the mechanism of the contraction.
For relaxation, Ca2? instead dissociates from troponin C
and leaves the cytosol through four different systems: SR
Ca2?-ATPase (SERCA2a); sarcolemmal Na?/Ca2?
exchanger (NCX); sarcolemmal Ca2?-ATPase; and mito-
chondrial Ca2? uniport [52]. T-tubules are invaginations in
the cell membrane located where L-type Ca2? channels
and RYR2 channels are close to each other and represent
one of the most important components of the Ca2? han-
dling system, contributing to ECC [56]. To date, although
hPSC-CMs express NCX at comparable levels of adult
cardiomyocytes [57], the SR is still poorly developed and
T-tubules have rarely been described. Consequently, Ca2?
handling kinetics as well as ECC are overall slow in hPSC-
CMs [58].
Responses to b-adrenergic stimulation
Sympathetic stimulation of the heart through b-adrenergic
receptor agonists, such as epinephrine, activates a mem-
brane stimulatory GTP-binding protein, which stimulates
adenylyl cyclase to produce cyclic adenosine monophos-
phate (cAMP), which, in turn, leads to the subsequent
activation of Protein Kinase A (PKA), therefore, potenti-
ating the cardiac Ca2? transients. In response to b-
adrenergic stimulation, adult cardiomyocytes display pos-
itive chronotropic (increase in beating frequency), positive
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inotropic (increase in contractility), and positive lusitropic
(acceleration of relaxation) effects [52]. Although hPSC-
CMs as well as fetal cardiomyocytes do exhibit chrono-
tropic responses to b-adrenergic stimulation [59, 60], they
do not show an increase in contraction or acceleration in
the relaxation period [61], unless when incorporated in
human EHTs as shown by Mannhardt [42]. These consid-
erations need to be taken into account when hPSC-CMs are
used for testing the efficiency of b-adrenergic drugs on the
cardiovascular system.
Mitochondrial function and metabolic profile
Due to its incessant contraction, the heart has an extremely
high energy demand compared to other tissues of the
human body [52]. Mitochondrial biogenesis increases over
time during heart development, so that in adult cardiomy-
ocytes, one-third of the cell volume is, indeed, occupied by
mitochondria [62]. Due to this change, during develop-
ment, glucose and lactate represent the predominant
substrates for the majority of ATP production in fetal
cardiomyocytes, while adult cardiomyocytes mainly use
fatty acids [63, 64]. Although hPSC-CMs still display an
immature phenotype, they also use fatty acids for the
majority of ATP production and mitochondrial density
increases over time, recapitulating to a certain extent the
development of the human heart [51, 65]. For this reason,
hPSC-CMs have successfully been used to recapitulate and
study the key aspects of mitochondrial and metabolic dis-
eases in humans, as Drawnel and colleagues have recently
showed by modeling diabetic cardiomyopathy and pheno-
typically screening drugs for a complication of type 2
diabetes [66].
Conduction velocity
While the parameters above can be evaluated in single
cells, the conduction velocity can only be measured in
monolayer cultures. Major factors contribute to determine
the conduction velocity of cardiomyocytes: propagation of
the electrical signal through Na? channels [67]; localiza-
tion of Na? channels and gap junction proteins [68];
localization, density, and composition of gap junction
proteins [69]; and cell size [70]. Although the composition
of gap junction proteins is similar in hPSC-CMs and adult
cardiomyocytes, Na? channels and gap junctions need to
be distributed at the edges of two adjacent cells (adult
cardiomyocytes) [71], rather than all around the cell cir-
cumference (fetal and hPSC-CMs). This, together with a
reduced availability of Na? channels due to a hyperpolar-
ized RMP and cell size, contributes to the slow conduction
velocity observed in hPSC-CMs [51]. Of note though,
several groups have addressed this issue by repolarizing the
RMP through overexpression or electronic enhancement of
IK1 as a robust method to obtain more physiological elec-
trical behaviour, including increased Na? channel
availability and improved Ca2? transients profile [72–75].
Importantly, IK1-enhanced hiPSC-CMs displayed a
stable RMP in the absence of spontaneous beating activity,
allowing more accurate quantitative analysis of AP in
comparing healthy and diseased myocytes [72–75]. In
addition, increased cell size, membrane capacitance, and
DNA synthesis were also observed [73].
Existing hiPSC models of cardiovascular and non-
cardiovascular diseases with cardiac traits
To date, hiPSC-CMs have successfully been used not only
to recapitulate, but also to better understand and elucidate
the disease-relevant cellular and molecular pathological
mechanisms of several cardiovascular diseases. They
remain one of the few opportunities to study the heart
against a background of human gene expression. Below, as
well as in Fig. 1 and Table 3, we list most of the hiPSC
cardiac models to date and provide specific examples.
Arrhythmias and channelopathies
Familial long-QT syndrome
Long-QT syndrome (LQTS) is a potentially life-threaten-
ing arrhythmia characterized by a prolongation in the
ventricular repolarization component (QT interval) of the
electrocardiogram (ECG) [76]. Patients affected by LQTS
experience polymorphic ventricular tachycardia with a
characteristic shape of the ECG also termed ‘‘Torsades de
Pointes’’, syncope, and sudden cardiac death. LQTS
includes hereditary variants: the autosomal-dominant form
or Romano–Ward syndrome and the recessive form or
Jervell and Lange-Nielsen syndrome (JLNS) [77–80].
LQTS is associated with more than 500 mutations in 16
different genes encoding cardiac ion channel proteins and
their auxiliary subunits or modulating proteins, and dis-
plays a wide range of phenotypes even within members of
the same family [81, 82].
LQT1
LQT1 patients harbor mutations in the KCNQ1 gene, which
encodes the K? channel Kv7.1 mediating the repolarizing
current Iks of the AP [83]. To date, several LQT1 hiPSC
lines have been generated and characterized from patients
carrying distinct mutations in the KCNQ1 gene, such as
R190Q [84, 85], G269S and G345E [85, 86], P631fs/33
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Fig. 1 Schematic representation of cardiomyocyte structure and
relevant cellular and molecular components that are mutated in
cardiac diseases. This schematic shows the cardiac proteins encoded
by mutated genes for which hiPSCs have been generated and
reviewed here. Disease genes of interest, which are also listed in
Table 3, are located in different compartments of the cardiomyocyte,
such as the extracellular matrix, sarcoplasmic reticulum (SR),
cytoskeleton, sarcomere, desmosome, lysosome, mitochondrion, and
the nucleus
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Table 3 Existing hiPSC models of cardiovascular diseases and disorders with cardiac traits
Disease Gene Mutation References
Arrhythmias and channelopathies
LQT1 KCNQ1 R190Q [84]
LQT1 KCNQ1 P631 fs/33 [87]
LQT1 KCNQ1 Ex7Del [88]
LQT1/JLNS KCNQ1 R594Q [111]
E160fs?138X




LQT2 KCNH2 G1681A [90, 91]
LQT2 KCNH2 R176W [93]
LQT2 KCNH2 A561V [95]
LQT2 KCNH2 N996I [94]
LQT2 KCNH2 A614V [92]
LQT2 KCNH2 A561P [97]
LQT2/LQT3 KCNH2 A422T [96]
SCN5A N406K
LQT2 TBX20 R311C [98]
LQT3 SCN5A V1763M [100]
LQT3 SCN5A V240M [102]
R535Q
LQT3 SCN5A F1473C [101]
KCNH2 K897T
LQT3 SCN5A R1644H [103]
LQT8/TS CACNA1C G1216A [107]
LQT14 CALM1 F142L [75]
LQT15 CALM2 D130G [110]
BrS/LQT3 SCN5A 1795insD [74, 118, 120, 242]
BrS/LQT3 SCN5A E1784K [121]
BrS SCN5A R620H/R811H [122]
4189delT
CPVT RYR2 M4109R [243]
CPVT RYR2 F2483I [126, 244]
CPVT RYR2 P2328S [245]








CPVT RYR2 L3741P [130]
CPVT RYR2 I4587V [131]
CPVT RYR2 E2311D [129]
CPVT CASQ2 G112?5X [132]
CPVT/LQTS TECRL SRD5A2L2 [133]
c.331?1G[A
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Table 3 continued
Disease Gene Mutation References
Cardiomyopathies
BTHS TAZ 517delG [137]
BTHS TAZ Gly197Val [136]
EX2Del
Arg57Leu
Leopard PTPN11 T468M [140]
ARVC PKP2 Gly828Gly [146]
R672fsX683
ARVC PKP2 L614P [144]
ARVC PKP2 A324fs335X [145]
ARVC SCN5A R1898H [147]
DCM TNNT2 R173W [152, 153]
DCM LMNA R225X [151]
DCM TTN W976R [156]
A22352fs
P2258fs
DCM DES A285V [154]
DCM RBM20 R636S [157]
HCM MYBPC3 C2373dipG [50]
HCM MYH7 Arg663His [159]
HCM BRAF T599R [163]
HCM BRAF T599R [164]
Q257R
DCM/HCM ALPK3 W1264X [166]
HCM PRKAG2 N488I [168]
R531Q
LQT1 KCNQ1 G269S [86]
HCM MYH7 R663H
DCM TNNT2 R173W
HCM MYH7 R442G [160]
HCM MYBPC3 Arg91Cys [161]
N/A
Gly999/Gln1004del
HLHS N/A N/A [169]
IHD/CAD ALDH2 ALDH2*2 [184]
Cardiometabolic diseases
PD GAA Ex18Del [190]
1441delT/TRP746TER
PD GAA Arg266Cys/M439K [194]
PD GAA D645E/D645E [189]
D645E/2040-1G
PD GAA Ex18del [193]
Danon LAMP2 129-130 insAT [198]
IVS-1 c.64?1 G[A
Fabry GLA W162X [201]
Fabry GLA W162X/R220X [202]
Fabry GLA IVS4?919 G[A [203, 204]
Diabetic cardiomyopathy N/A N/A [66]
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[87], and a novel heterozygous exon 7 deletion (ex7Del)
[88].
In 2010, Moretti and colleagues used retroviral vectors
to generate patient-specific hiPSCs from members of a
family affected by the autosomal-dominant missense
mutation R190Q in the KCNQ1 gene and differentiated the
patient-derived cells into functional cardiomyocytes that
recapitulated in vitro electrophysiological features of the
LQT1 disease phenotype and the therapeutic approach of
b-blockade [84]. In the same study, hiPSC-CMs helped
demonstration of a dominant negative trafficking defect of
the mutated channel. Similarly, Egashira et al. identified
the same molecular mechanism as being responsible of an
LQT1 phenotype in P631fs/33-KCNQ1 mutated hiPSC-
CMs [87]. In another study, Liang and colleagues gener-
ated a library of hiPSC-CMs from healthy individuals and
patients with different hereditary cardiac disorders,
including LQT1, for recapitulating and predicting drug-
induced arrhythmia. Interestingly, these cells displayed a
broad spectrum of cardiotoxicity effects suggesting that
disease-specific hiPSC-CMs may accurately predict
adverse drug-induced cardiotoxicity [86]. Furthermore, in
2014, Wang et al. generated hiPSCs by overexpressing ion
channel genes with dominant negative mutations causing
LQT1 (G269S, G345E, and R190Q). To achieve
stable transgene expression, these genes were integrated
into the AAVS1 safe harbor locus using the Zinc Finger
Nuclease technology. Next, transgene cells and isogenic
unedited controls were differentiated into cardiomyocytes
and recapitulated the LQT1 disease phenotype showing a
prolongation in the AP duration (APD) [85].
LQT2
LQT2 patients carry mutations in the KCNH2 gene, also
termed human ether-a-go-go related gene (hERG), which
encodes the K? channel mediating the repolarizing current
Ikr of the AP [89]. A panel of LQT2-diseased hiPSCs
carrying the following hERG mutations has been generated
and characterized: G1681A [90, 91], A614V [85, 92],
R176W [93], N996I [94], A561V [95], A422T [96], and
A561P [97].
By performing multi-electrode array, patch-clamp
electrophysiology, and drug testing, Matsa et al. demon-
strated that hiPSC-CMs from two patients carrying the
G1681A KCNH2 mutation showed prolonged APs but
displayed different drug-induced sensitivity [90, 91]. Two
independent laboratories applied similar strategies for
modeling LQT2 by generating hiPSCs from patients car-
rying the missense A614V [92] and R176W [93] mutations
on the hERG channel. However, despite the novelty of
using patient hiPSC-CMs for modeling LQT2, these stud-
ies were performed under genetically non-defined
conditions and, therefore, genetic background variations
were not taken into account. To address this limitation, we
modeled LQT2 syndrome by generating hiPSCs from a
patient carrying the N996I hERG missense mutation and
corrected the mutation by homologous recombination.
Next, we introduced the same mutation in hESCs, gener-
ating two genetically distinct isogenic pairs of LQTS and
control lines [94]. This approach allowed the electrophys-
iological changes to be attributed to the specific mutation.
In another study, hiPSCs were derived using a virus-free
method from patients with the A561V missense mutation
in the KCNH2 gene and they differentiated them into
beating cardiomyocytes. Notably, this study provided an
approach to rescue the diseased LQT2 phenotype correct-
ing hERG trafficking defects with the pharmacological
agent ALLN, demonstrating with patient-specific hiPSC-
CMs that re-trafficking of the mutated channels might
represent an alternative approach for some KCNH2 muta-
tions [95].
Recently, the use of hiPSC-CMs for modeling LQT2
helped revealing a key role for the transcription factor
Table 3 continued
Disease Gene Mutation References
Non-cardiovascular diseases with cardiac traits
DMD DMD Ex50Del [212]
DMD DMD Ex45-52del [213]
ATTR TTR L55P [215]
A search for original articles published up to February 2017 was performed using PubMed Advanced Search Builder using the following criteria:
(i) (human-induced pluripotent stem cells) AND (cardiac disease model) NOT review; (ii) (human-induced pluripotent stem cells) AND
(cardiomyocytes) NOT review; (iii) (human-induced pluripotent stem cells) AND (cardiomyocytes) AND (mechanistic insight) NOT review.
References on cardiac regeneration were manually excluded. References from some of the most comprehensive reviews of the field were
screened and manually added when not present in the above-mentioned search. Limitation of this review relates to selection bias
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TBX20 in the regulation of KCNH2 expression [98]. In this
study, Caballero and colleagues investigated the electro-
physiological effects of the R311C-TBX20 mutation,
which is found in individuals affected by LQTS, in hiPSC-
CMs. The authors showed that the R311C mutation
specifically disables the posttranscriptional activity of
TBX20 over KCNH2, which decreases the IKr and prolongs
the AP, therefore, identifying TBX20 as an LQT2-modi-
fying gene [98].
LQT3
LQT3 patients usually carry gain-of-function mutations in
the SCN5A gene, which encodes the Na? channel NaV1.5
mediating the fast depolarizing current INa during AP [99].
To date, several SCN5A mutations have been modeled
with patient-specific hiPSC-CMs: V1763M [100], F1473C
[101], V240M and R535Q [102], and R1644H [103].
In 2013, Ma and colleagues derived hiPSC-CMs from an
LQT3 patient harboring a V1763M-SCN5A mutation and
recapitulated the biophysical abnormalities (prolonged APD,
increased tetrodotoxin (TTX)-sensitive late or persistent
Na? current, positive shift of steady-state inactivation, and
faster recovery from inactivation) of the disease. In this
study, the hiPSC line was generated from dermal fibroblasts
of the patient and control-hiPSC-CMs were derived from the
healthy sister of the patient [100]. However, LQTS may
occur in families whose members are affected by multiple
mutations and complex genetics. Such disease phenotypes
are difficult to recapitulate in vitro; moreover, the develop-
ment of patient-specific clinical regimens remains
challenging. To address these limitations, hiPSC-CMs have
been generated from family members with complex genet-
ics, such as reported by Terrenoire et al. [101]. In this study,
hiPSCs were derived from an LQTS patient harboring the
F1473C SCN5A mutation and the K897T KCNH2 poly-
morphism. Notably, analysis of the biophysics and
molecular pharmacology of ion channels expressed in car-
diomyocytes differentiated from these cells displayed a
primary LQT3 Na? channel defect responsible for the
patient’s arrhythmias, which was not influenced by the
KCNH2 polymorphism. In a similar manner, Fatima et al.
reported the generation of hiPSCs from two LQT3 patients
carrying two distinct mutations in SCN5A (V240M and
R535Q), which resulted in defective biophysical properties
of Nav1.5 [102]. Furthermore, in a large family affected by
congenital LQT3 syndrome, 15 out of the 23 available
individuals were identified as heterozygous carriers of the
missense mutation R1644H in SCN5A. Of note, Malan and
colleagues obtained skin biopsies from one member of this
family affected by LQT3, as well as from one healthy
control individual of the same family [103]. Of particular
interest, after addition of mexiletine, a Na? channel inhibitor
commonly used in LQT3 therapy, a shortening in the APD
was noticed in LQT3 hiPSC-CMs, which successfully res-
cued the disease phenotype of the patient.
LQT8/Timothy syndrome (TS)
LQT8, also known as Timothy syndrome (TS), is a complex
multi-system disorder characterized by QT prolongation,
webbed fingers and toes, flattened nasal bridge, low-set ears,
small upper jaw, thin upper lip, and typical autism traits
[104, 105]. TS patients carry mutations in the CACNA1C
gene, which encodes the Ca2? channel CaV1.2, the main
L-type Ca2? channel in the mammalian heart responsible for
the plateau phase of the AP and essential for ECC [106].
Yazawa and colleagues successfully modeled the cardiac
phenotype of TS including irregular contraction and elec-
trical activity, and abnormal Ca2? handling by generating
hiPSC from a patient harboring a G1216A missense muta-
tion in CACNA1C [107]. Of particular interest, the small
molecule roscovitine proved successful in restoring normal
electrical and Ca2? properties.
LQT14
Patients carrying mutations in one of the three genes
encoding calmodulin (CaM, a multifunctional intermediate
Ca2?-binding messenger protein essential for the func-
tionality of the heart, immune system, and brain) manifest
cardiac arrhythmias associated with severe LQTS, as well
as catecholaminergic polymorphic ventricular tachycardia
and idiopathic ventricular fibrillation [108–110]. Mutations
in the CALM1 gene, encoding CaM, are associated with
type 14 LQTS (LQT14). In this regard, Rocchetti and
colleagues recently investigated the unclear arrhythmo-
genic effect of the heterozygous F142L mutation in
CALM1 by studying patient-specific hiPSC-CMs electro-
physiology with addition of stimulated Ik1 by Dynamic-
Clamp [75]. Mutated hiPSC-CMs displayed loss of IcaL
inactivation and abnormal APD, whilst Iks and INaL
remained unaltered. IcaL blockage rescued the disease
phenotype. Importantly, these findings demonstrated that
F142L-CaM arrhythmogenesis is caused by loss of IcaL
inactivation [75].
LQT15
CALM2 mutations are associated with type 15 LQTS
(LQT15). In a recent study, Limpitikul and colleagues
generated hiPSC-CMs from a patient carrying the D130G-
CaM mutation within the CALM2 gene. Notably, the
patient-derived iPSC-CMs showed prolongation of the
APD and disruption of Ca2?/CaM-dependent inactivation
(CDI) of L-type Ca2? channels. Importantly, allele-specific
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suppression of the mutated CALM2 gene using CRISPR
interference resulted in functional rescue in the hiPSC-
CMs, with normalization of APD and CDI after treatment
[110].
JLNS
The Jervell and Lange-Nielsen syndrome is inherited as an
autosomal recessive trait and is characterized by a severe
QT interval prolongation at the ECG and by deafness [78].
JLNS patients harbor homozygous or compound
heterozygous mutations in KCNQ1 or KCNE1 genes. In
one study, both patient-derived and engineered hiPSCs
carrying the E160fs ? 138X or the R594Q KCNQ1
mutations recapitulated the severe JLNS electrophysio-
logical phenotype including APD prolongation and drug-
induced arrhythmia susceptibility [111].
Brugada syndrome
Brugada syndrome (BrS) is an inheritable channelopathy
characterized by a coved-type ST-segment elevation in the
right precordial leads of ECG and increased risk of sudden
cardiac death from ventricular fibrillation [112, 113]. Loss-
of-function mutations in the SCN5A gene encoding the Na?
channel responsible for the cardiac INa are associated with
BrS; they account for *20% of cases [114, 115]. Genetic
alterations in additional genes encoding Na?, K?, and
Ca2? channels or associated proteins have been linked to
BrS [116]; however, *70% of BrS patients remain
genetically unsolved, suggesting that additional factors,
such as copy number variations, mutations in yet-unknown
genes, epigenetic factors, and post-translational modifica-
tions may contribute to this disease [117].
The 1795insD SCN5A mutation underlying both BrS and
LQT3 was identified in a large Dutch family with ECG fea-
tures of bradycardia and ventricular and atrial conduction
slowing [118, 119]. In a study performed by Davis and col-
leagues, hiPSC were generated from a patient carrying the
1795insD mutation and differentiated toward cardiomyocytes
that displayed the overlapped INa and AP properties of both
BrS and LQT3 channelopathies (decrease in INa density, large
persistent INa, reduced upstroke velocity, and prolonged APD)
[120]. Similarly, Okata et al. generated hiPSCs from a patient
carrying the E1784K SCN5A mutation, which has previously
been associated with the mixed phenotype of LQT3/BrS.
Interestingly, electrophysiological analysis showed that
LQT3/BrS-hiPSC-CMs recapitulated the phenotype of LQT3
but not BrS. Due to the fact that SCN3B is the predominant
Na? channel b-subunit in fetal hearts as well in hiPSC-CMs,
while SCN1B is the predominant b-subunit in the adults, the
knockdown of SCN3B in the LQT3/BrS-hiPSC-CMs suc-
cessfully unmasked the phenotype of BrS. Moreover,
corrected-LQT3/BrS-hiPSC-CMs exhibited the normal elec-
trophysiological phenotype [121].
In another study of interest, Liang and colleagues gen-
erated hiPSC-CMs from two patients affected by BrS; the
first patient carrying the double missense mutation (R620H
and R811H) in SCN5A and the second patient carrying one
base-pair deletion mutation in SCN5A (4189delT) [122].
Importantly, BrS iPSC-CMs successfully recapitulated
features of the BrS disease, such as the reduction of inward
Na? current density and reduction of maximal upstroke
velocity, increased triggered activity and abnormal Ca2?
handling [122].
However, a dysfunction in the cardiac Na? channel may
not always represent a prerequisite for BrS phenotype
in vitro, as demonstrated by Veerman and colleagues [74].
In this study, a comparison of electrophysiological prop-
erties between hiPSC-CMs generated from three patients
affected by BrS and two unrelated controls revealed no
significant differences in INa and in upstroke velocity,
therefore, indicating that the BrS phenotype here could not
be recapitulated in the hiPSC model. These results led to
the hypothesis that other mechanisms than ion channel
defects might underlie the phenotype in these patients, such
as fibrosis, decreased cardiomyocyte coupling, and envi-
ronmental factors; alternatively, or in addition, immaturity
of hiPSC-CMs might have hampered the detection of the
disease phenotype.
Catecholaminergic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is an inherited cardiac disorder characterized by
ventricular tachyarrhythmia, syncope and sudden cardiac
death usually induced by emotional and physical stress
[105, 123]. CPVT is caused by mutations in the RYR2 gene,
which leads to the CPVT1 variant, or by mutations in the
calsequestrin-2 gene (CASQ2), which leads to the CPVT2
variant [124]. As previously mentioned, RYR2 encodes the
principal Ca2? releasing channel expressed in the mem-
brane of the SR, while CASQ2 encodes a high-capacity and
low-affinity Ca2?-binding glycoprotein of the SR, both key
players in ECC [125].
To date, several models of patient-specific hiPSC-CMs
carrying RYR2 mutations have been generated. Impor-
tantly, all these studies successfully demonstrated that
hiPSC-CMs can recapitulate some of the Ca2? handling
abnormalities typical of CPVT1 and, therefore, opened
new opportunities for the investigation of the disease
mechanisms in vitro as well as for drug testing. As an
example, Fatima and colleagues demonstrated that patient-
specific hiPSC-CMs harboring the F2483I mutation in the
RYR2 channel displayed arrhythmias and delayed after
depolarizations (DADs) post-catecholaminergic
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stimulation, and higher amplitudes and longer durations of
spontaneous Ca2? release events at basal state when
compared to healthy controls. Of note, these Ca2? release
events continued even after repolarization and were abol-
ished by increasing the cytosolic concentration of cAMP
with forskolin, an adrenergic stimulator that acts via pro-
duction of cAMP [126]. In another study of interest, Jung
and colleagues successfully restored normal Ca2? spark
properties and rescued the arrhythmogenic S406L RYR2
phenotype by addition of dantrolene, a drug against
malignant hyperthermia. Moreover, their findings sug-
gested that the pathogenesis of the S406L mutation is due
to a defect of inter-domain interactions within the RYR2
channel [127]. The antiarrhythmic effect of dantrolene was
also assessed by Penttinen and colleagues in six patients
carrying various RYR2 mutations and in their correspond-
ing hiPSC-CM models [128]. This study showed similar
patient-to-patient variation in dantrolene effects both in the
patients and in the corresponding iPSC-CMs, suggesting
that it may be possible to predict personalized drug-dose
responses in vitro without predisposing the patient to the
potentially severe side-effects of a drug [128]. In another
study, Di Pasquale et al. developed a model of CPVT1 by
generating hiPSCs from a patient harboring the E2311D
RYR2 mutation. Treatment of hiPSC-CMs with KN-93, a
specific antiarrhythmic drug that inhibits Ca2?/calmodulin-
dependent serine–threonine protein kinase II (CaMKII),
decreased DADs, and successfully rescued the arrhythmic
phenotype induced by catecholaminergic stress [129].
Interestingly, a recent study performed by Preininger and
colleagues revealed the inadequacy of b-blocker treatment
by nadolol in one patient affected by a novel mutation in
RYR2 that causes CPVT1 [130]. hiPSC-CMs generated
from the patient showed persistent ventricular arrhythmias
during b-blockade with nadolol, whereas no arrhythmias
were observed during treatment with the Na? channel
blocker flecainide. In detail, nadolol treatment during b-
adrenergic stimulation achieved negligible reduction of
Ca2? wave frequency and failed to rescue the Ca2? spark
defects in diseased hiPSC-CMs. On the other hand, fle-
cainide reduced both frequency and amplitude of Ca2?
waves and restored the Ca2? sparks to the baseline levels
[130], closely recapitulating drug treatment in the patient.
In a similar manner, Sasaki and colleagues combined
electrical pacing with CPVT- and control-hiPSC-CMs to
validate S107, a drug that stabilizes the closed state of the
RYR2, as potential therapeutic agent for CPVT1 [131].
After proving the efficacy of Adeno-associated virus
(AAV)-mediated CASQ2 gene replacement therapy for
CPVT2 in mouse models, Lodola and colleagues inves-
tigated the efficacy of this strategy in hiPSC-CMs
generated from a patient carrying the homozygous
G112?5XCASQ2 mutation [132]. HiPSC-CMs infection
with AAV carrying the wild-type CASQ2 gene revealed to
be sufficient to restore the physiological expression of
CASQ2 protein, and to observe decrease in the percentage
of DADs following adrenergic stimulation as well as
normalization of Ca2? transient amplitude and Ca2?
sparks. These findings show the potential of gene therapy
as curative approach in patients affected by some CPTV
mutations [132].
CPVT/LQTS—A recent study by Devalla and col-
leagues was carried out on hiPSC-CMs from patients from
three different families with clinical arrhythmias and high
risk of sudden cardiac death [133]. Precisely, two of these
patients were diagnosed with LQTS, whereas the third
patient belongs to a family diagnosed with the early onset
and highly malignant form of CPVT. Of note, all of them
carried mutations in the gene encoding the trans-2,3-
enoyl-CoA reductase-like protein (TECRL gene), whereas
no mutations in the most common LQTS and CPVT
genes. Analysis of intracellular Ca2? dynamics, AP
measurements, stimulation by noradrenaline, and treat-
ment with the antiarrhythmic drug flecainide in the
patient-specific hiPSC-CMs recapitulated the clinical
phenotypes of LQTS and CPVT, showing, for the first
time, that mutations in the TECRL gene are associated
with inherited arrhythmias with clinical features of both
LQTS and CPVT [133].
Cardiomyopathies
Barth syndrome
Barth syndrome (BTHS) is an X-linked cardiac and
skeletal mitochondrial myopathy caused by mutations of
the gene Tafazzin (TAZ) [134] responsible for remodeling
cardiolipin, the major phospholipid of the mitochondrial
inner membrane [135]. To date, two independent studies
generated BTHS hiPSCs [136, 137]. Interestingly, Wang
and colleagues recapitulated the pathophysiology of BTHS
cardiomyopathy by combining patient-derived hiPSCs with
genome editing, modified RNAs, and ‘‘heart on a chip’’
technologies [137]. They demonstrated that a mutation in
TAZ gene (517delG) is sufficient to disassemble the
structure of the cardiomyocyte sarcomeres. Furthermore,
they demonstrated that BTHS cardiomyopathy can be
reversed by either reintroducing the wild-type TAZ gene, or
by suppressing the level of reactive oxygen species (ROS)
produced by BTHS mitochondria. In another study of
interest, Dudek and colleagues studied mitochondrial
oxidative phosphorylation in BTHS-hiPSC-CMs, which
displayed a severe decrease in basal oxygen consumption
rate and in the maximal respiratory capacity when com-
pared to wild-type cells, leading to a dramatic increase of
ROS production [136].
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Leopard syndrome
LEOPARD is the acronym of ‘‘Lentigines, Electrocardio-
graphic abnormalities, Ocular hypertelorism, Pulmonary
valve stenosis, Abnormal genitalia, Retardation of growth,
Deafness’’, an autosomal-dominant disease that belongs to
a class of disorders associated with RAS–mitogen-acti-
vated protein kinase signaling [138, 139]. Approximately
90% of LEOPARD syndromes are caused by missense
mutations in the PTPN11 gene, which encodes the ubiq-
uitously expressed tyrosine phosphatase protein SHP2,
although hypertrophic cardiomyopathy remains the most
common abnormality in patients affected by LEOPARD
syndrome [139]. Against this background, Carvajal-Ver-
gara and colleagues generated hiPSCs from two patients
with the heterozygous T468M mutation in the PTPN11
gene and highlighted important molecular mechanisms in
the signaling pathways responsible for the cardiac hyper-
trophic phenotype in LEOPARD syndrome, such as the
increased phosphorylation of specific proteins such as
MEK1 in LEOPARD-hiPSC-CMs compared to wild-type,
demonstrating that RAS-MAPK signaling is perturbed in
LEOPARD syndrome [140].
Arrhythmogenic right ventricular cardiomyopathy
Another inherited cardiac disorder that has been modeled
with hPSC-CMs is the arrhythmogenic right ventricular
cardiomyopathy (ARVC), characterized by the replace-
ment of cardiomyocytes with fatty or fibrofatty tissue
[141]. Approximately half of the patients affected by
ARVC carry a mutation in one of the genes encoding for
key components of the desmosome, the intercellular junc-
tion of cardiac muscle [142, 143]. Of note, different
laboratories studied ARVC hiPSCs from patients with
mutations in the PKP2 gene, which encodes the plako-
philin-2 desmosomal protein [144–146]. In these studies,
fibroblasts were reprogrammed into hiPSC via retrovirus
infection and cardiomyocytes were generated using 3D
protocols of differentiation. Gene expression profiling,
immunofluorescence staining of desmosomal proteins,
transmission electron microscopy, and exposure of the cells
to apidogenic stimuli allowed these scientists to success-
fully recapitulate the ARVC phenotype in vitro and
provided mechanistic insights into the early disease
pathogenesis, such as the association of ARVC phenotype
with the upregulation of the pro-adipogenic transcription
factor peroxisome proliferator-activated receptor-c (PPAR-
c) [145].
Notably, it has recently been suggested an interaction
between the desmosome and the Na? channel protein
Nav1.5 encoded by the SCN5A gene, raising the hypothesis
that mutations in this Na? channel complex may lead to
ARVC cardiomyopathy [147]. On this note, Riele and
colleagues generated hiPSC-CMs from an ARVC patient
harboring the rare mutation (R1898H) in SCN5A and no
desmosomal mutations. In this study, the authors demon-
strated reduced Na? current and Nav1.5/N-Cadherin
clusters at junctional sites in the patient-derived hiPSC-
CMs, suggesting that Nav1.5 may be part of a functional
complex with adhesion molecules such as N-Cadherin,
which reveals a non-canonical mechanism by which
SCN5A mutations lead to ARVC cardiomyopathy [147].
Familial dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is an inherited cardiac
disorder that mostly affects the myocardium. It is charac-
terized by left or biventricular dilatation, which is sufficient
to cause global systolic impairment [148]. DCM is a
genetically heterogeneous disease that can be caused by
mutations in many different genes [149]. One of the key
genes identified in familial DCM is LMNA, which encodes
intermediate filament proteins of the nuclear lamina, the
‘‘lamin A/C proteins’’ [150]. Two different LMNA muta-
tions, the autosomal-dominant non-sense R225X and a
frame shift mutation, were investigated in a work from Siu
and colleagues [151]. This study revealed that haploin-
sufficiency due to R225X mutation was associated with
accelerated nuclear senescence and apoptosis of patient-
specific hiPSC-CMs under electrical stimulation, which
was attenuated by pharmacological blocking of ERK1/2
signaling pathway. Another gene associated with DCM is
TNNT2. So far, three independent groups succeeded in
showing hypertrophic signatures in hiPSC-CMs carrying
the R173W TNNT2 mutation [86, 152, 153]. Furthermore,
as demonstrated by Tse and colleagues, patient-specific
hiPSC-CMs can be used to confirm histological and func-
tionally suspected genetic bases for DCM [154]. In this
study, using whole-exome sequencing, Tse et al. identified
the novel heterozygous mutation A285V in the muscle-
specific intermediate filament protein Desmin (encoded by
the DES gene) responsible for the cytoskeletal organization
between cardiomyocytes and striated muscle cells [155].
Nevertheless, the most common genetic cause for DCM
consists of mutations that truncate the massive sarcomeric
protein Titin (encoded by the TNN gene), the so-called
‘‘TTN-truncating variants’’ (TTNtvs), such as the W976R,
A22352fs, and P2258fs mutations, studied by Hinson and
colleagues [156]. Here, RNA sequencing and functional
analyses were combined with cardiac engineered micro-
tissues from healthy, mutated, and isogenic hPSC lines to
demonstrate that truncations in the A-band domain of TTN
cause DCM, whereas truncations in the I band are better
tolerated, because alternative splicing excludes I-band
exons from most mature TTN transcripts [156]. Finally, by
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investigating stage-specific cardiogenesis in hiPSC carry-
ing mutations in the RNA-binding motif protein 20 gene
(RBM20), Wyles et al. showed that in this specific case,
DCM is a developmental disorder [157].
Familial hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is an inherited car-
diac disorder that can be caused by more than 1400
mutations in at least 11 genes encoding the thick and thin
contractile myofilaments or the Z-discs of the sarcomere,
leading to an abnormal thickness of the myocardial left
ventricle [158]. Although the majority of individuals
affected by HCM are asymptomatic or manifest mild
symptoms, they are equally exposed to a high risk of
progressive heart failure, arrhythmia, and sudden cardiac
death [105]. However, the pathways by which sarcomeric
mutations induce cardiomyocyte hypertrophy and electro-
physiological abnormalities are still not completely clear
[159]. Therefore, the generation of patient-specific hiPSC-
CMs to model HCM may help to elucidate and, maybe, in
the future, to predict the onset and the development of
HCM, as demonstrated by Lan and colleagues [159]. In this
study, hiPSC-CMs were generated from patients harboring
the missense R663H MYH7 mutation. These cells showed
enlarged cell size and contractile arrhythmia at the single-
cell level. Furthermore, Ca2? analysis revealed deregula-
tion of Ca2? cycling and Ca2? intracellular concentration,
and key mechanisms of HCM pathogenesis. Similarly, two
other groups recapitulated the disease phenotype of HCM
by generating hiPSC-CMs from patients carrying mutations
in the MYH7 gene [86, 160].
In two other studies, hPSC-CMs carrying a mutation in
MYBPC3, the gene encoding the cardiac myosin-binding
protein C, were generated [50, 161]. After generating
hPSC-CMs from three patients with HCM, Tanaka and
colleagues demonstrated that the HCM phenotype as well
as the contractile variability observed in the three classes of
HCM hPSC-CMs were caused by interactions between the
patient’s genetic backgrounds and the cardiomyocyte
hypertrophy-promoting factor endothelin-1 [161]. In
another study of interest, Birket and colleagues showed
that, under optimized conditions for cardiomyocyte func-
tion, which included the presence of thyroid hormone,
insulin growth factor-1, and dexamethasone, single HCM
hPSC-CMs showed lower contractile force when compared
to controls [50].
HCM can also affect individuals with cardiofaciocuta-
neous syndrome (CFCS), a genetic disease characterized
by abnormal RAS/MAPK signaling in multiple populations
of cardiac cell progenitors [162]. In a recent study, Cash-
man et al. generated a 3D model of human engineered
cardiac tissue, termed ‘‘hECT’’, using hiPSC-CMs from
patients carrying BRAF mutations and presenting with
CFCS and HCM [163]. After 1 week in culture, BRAF-
hECTs exhibited several structural, molecular, and func-
tional features of hypertrophic phenotype when compared
to hECTs derived from healthy individuals (larger cross-
sectional area, increased expression level of the hyper-
trophic marker ANP, increased expression of the
hypertrophic marker BNP, and the Ca2? regulatory marker
SERCA2a, as well as greater developed force, shorter
twitch duration, and higher maximum rates of contraction
and relaxation). Furthermore, a model consisting on
BRAF-mutated hiPSC-CMs not only recapitulated the
disease phenotype of HCM, but also helped elucidating the
role of RAS/MAPK signaling in HCM pathogenesis [164].
Here, Josowitz and colleagues demonstrate that activation
of this pathway through TGFb signaling leads to car-
diomyocyte hypertrophy driven by both autonomous and
non-autonomous cardiomyocyte defects. Importantly, these
findings suggest a potential therapeutic use of TGFb inhi-
bitors in HCM and CFCS patients, for which no curative
options exist to date [164].
Another study conducted on three unrelated families
demonstrated that pediatric HCM can be caused by bial-
lelic truncating mutations in the gene encoding the a-
kinase-3 (ALPK3) [165]. Notably, several features of
DMC, such as alterations in the systolic function, were also
found in the same individuals, suggesting a role for the
ALPK3 pathway in the pathogenesis of a mixed DCM/
HCM phenotype. Subsequently, Phelan et al. derived car-
diomyocytes from a consanguineous family harboring a
novel biallelic truncating mutation, and from hESCs lack-
ing ALPK3. Ultrastructural analysis, multi-electrode array,
and Ca2? imaging on these cells revealed disorganized
sarcomere structures and intercalated discs, extended field
potential duration, and increased irregular Ca2? transients
(arrhythmia) indicative of abnormal Ca2? handling. Col-
lectively, this study suggests that mutations in ALPK3 can
cause familiar cardiomyopathy, identifying abnormal Ca2?
handling as a potential feature of cardiomyocytes lacking
ALPK3 [166].
In addition, several missense mutations causing HCM
have been observed in the gene encoding PRKAG2, one of
the three regulatory subunits of the AMP-activated protein
kinase (AMPK) that is highly expressed in the heart and
involved in glucose handling and mitochondrial biogenesis
[167]. Using hiPSC-CMs, three-dimensional cardiac
microtissues, RNA sequencing, and metabolomics, Hinson
and colleagues recently revealed key links between AMPK
and cardiomyocyte survival and metabolism with TGFb
signaling. By demonstrating that AMPK inhibits TGFb
production and fibrosis in vivo, the authors suggest that
molecules that activate AMPK may be beneficial for the
treatment of fibrosis and HCM [168].
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Hypoplastic left heart syndrome
Hypoplastic left heart syndrome (HLHS) is characterized
by underdevelopment of the left side of the heart which can
lead to variable complications like hypoplasia or atresia of
the left ventricle, ascending aorta, and aortic and mitral
valves [169]. It has been suggested that HLHS may be due
to a diminished blood flow through the left side of the heart
[170, 171], or to the disruption of specific genetic networks
required for left ventricular chamber development
[172, 173]. In a study from Jiang and colleagues, dermal
fibroblasts were obtained from the skin biopsy of one
HLHS patient and were reprogrammed to hiPSCs [169].
Interestingly, mutated hiPSC-CMs displayed gene expres-
sion and functional differences when compared to healthy
control cardiomyocytes: reduced expression of CX43 and
cTnT; higher expression of CD31 and embryonic atrial
myosin essential light chain (ALC-1); higher expression of
MYH6 and decreased expression of MYH7; lower numbers
and beating rates of contractile areas; accelerated rate of
Ca2? transient decay; RYR2 dysfunction; and upregulation
of IP3-receptor expression. Collectively, these findings
demonstrated that HLHS-disease hPSC-CMs show devel-
opmental and/or functional defects that could compromise
their ability to contribute to normal cardiogenesis in vivo.
Ischemic heart damage and coronary artery disease
A decrease of oxygen concentration in the heart tissue
dramatically alters the metabolism of cardiomyocytes by
producing high oxidative stress. To date, it is known that
oxidative stress and ROS play a key role in Ischemic Heart
Damage (IHD) and Coronary Artery Disease (CAD)
pathogenesis [174]. Indeed, during Myocardial Infarction
(MI), ROS cause oxidative damage such as lipid peroxi-
dation and enhanced production of toxic aldehydes
[175–177]. Moreover, the high concentration of ROS
during ischemia–reperfusion triggers apoptosis and necro-
sis in the heart tissue [178].
Because of the more complex nature of IHD and CAD
compared with cell-autonomous genetic cardiac diseases,
IHD and CAD are more difficult to recapitulate in vitro
with hiPSC–CMs [179]. Nevertheless, some examples are
starting to emerge, suggesting that some aspects might be
recapitulated and elucidated in a culture dish. Interest-
ingly, IHD and increased risk of CAD have been linked to
the single-nucleotide polymorphism E487K in the car-
dioprotective enzyme aldehyde dehydrogenase-2
(ALDH2*2) [180–183]. Ebert et al. generated hiPSC-CMs
carrying the heterozygous ALDH2*2 allele and showed
that, under ischemic conditions, these cells displayed high
levels of ROS and toxic aldehydes, which led to cell cycle
arrest and activation of apoptotic signaling pathways
[184]. These findings highlighted the key role of ALDH2
in modulating cell survival decisions. Overall, these
insights into molecular mechanisms of ALDH2*2-related
ischemic damage might be useful for the development of




Pompe disease (PD) is an autosomal recessive disorder
caused by mutations in the gene encoding the lysosomal
glycogen-degrading enzyme, acid a-glucosidase (GAA)
[185, 186]. Patients affected by PD manifest reduced GAA
activity, increased cytoplasmic glycogen level, mitochon-
drial aberrance, and progressive autophagy [187]. PD can
be classified either as infantile-onset form, characterized by
progressive weakness of skeletal muscle and cardiac
hypertrophic cardiomyopathy, or late-onset form, and
characterized by later and slower progressive weakness of
skeletal muscle [188]. Importantly, the first hiPSC model
of PD was generated by Huang and colleagues [189]. Since
the heart is one of the most affected organs especially in
the infantile-onset form of PD, Huang et al. examined
whether cardiomyocytes derived from infantile PD-hiPSCs
exhibited the pathophysiological features of the disease by
comparing their GAA activity, glycogen content, mito-
chondrial function, and ultrastructural changes with healthy
hiPSCs-CMs. PD-hiPSC-CMs displayed depressed GAA
activity, higher glycogen content, lower oxygen con-
sumption rate, lower extracellular acidification rate, and
some but not all the ultrastructural abnormalities, such as
freely dispersed glycogen [189]. Since the mechanism by
which loss of GAA activity causes cardiomyopathy in the
infantile-onset form of PD is not well understood, Raval
and colleagues reprogrammed fibroblasts from patients
affected by infantile PD and generated additional hiPSCs-
CMs to gain further insight into the molecular mechanisms.
Unexpectedly, they found that the lysosome-associated
membrane proteins LAMP1 and LAMP2 from PD-hiPSC-
CMs displayed higher electrophoretic mobility compared
with healthy hiPSC-CMs. Collectively, this study sug-
gested that PD-hiPSC-CMs produce LAMPs lacking
appropriate glycosylation and that misglycosylation in
these proteins may contribute to the pathophysiology of
Pompe cardiomyopathy [190]. Although it has been
reported that cardiovascular complications mostly affect
the infantile-onset form of PD, several groups demon-
strated that late-onset PD patients can also be affected,
although in a less severe and frequent manner [191, 192].
To investigate this, Sato and colleagues generated late-
onset PD-hiPSCs and successfully differentiated
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cardiomyocytes from both PD and control hiPSCs.
Importantly, massive accumulation of glycogen in the
lysosome of cardiomyocytes derived from PD-hiPSCs, not
from control, was observed, but there were no significant
differences in the structure of the cardiomyocyte fiber, such
as disarray and hypertrophy. In another study of interest,
Higuchi et al. compared hiPSCs generated from patients
with infantile- and late-onset forms of PD [193]. Notably,
ultrastructural features of these hiPSCs revealed massive
accumulation of glycogen granules in the lysosomes of
patients affected by infantile PD, and a few lysosomes in
patients affected by the late-onset form of the disease.
Collectively, these data show that cellular pathology of
late-onset PS is reflected in patient-specific hiPSC-CMs
[194]. Furthermore, when treated with recombinant human
GAA (rhGAA), glycogen granules of infantile hiPSCs
significantly decreased in a dose-dependent manner, con-
firming that enzyme replacement therapy improves the
survival period as well as the muscle symptoms in some
PD patients [195].
Danon disease
Danon disease is a familial cardiomyopathy characterized
by impaired autophagy due to mutations in the gene
encoding the lysosomal-associated membrane protein type
2 (LAMP2) [196, 197]. Patients affected by Danon disease
display severe cardiac and skeletal muscle abnormalities
resulting in heart failure and consequent sudden cardiac
death [198].
Hashem and colleagues generated five independent
hiPSC lines from two patients affected by Danon disease
and compared them with two wild-type hiPSC lines
derived from healthy unrelated individuals [198]. Impor-
tantly, all healthy and disease hiPSC-CMs expressed the
cardiac-specific contractile protein a-actinin, but only
Danon hiPSC-CMs lacked LAMP2 protein. Next, size,
gene expression and functionality of hiPSC-CMs were
examined to investigate whether they recapitulated the
heart failure phenotype observed in Danon patients.
Cytological analysis revealed that Danon hiPSC-CMs were
significantly larger compared to healthy hiPSC-CMs,
therefore, recapitulating the hypertrophy observed in the
patients. Furthermore, some but not all Danon hiPSC-CMs
exhibited longer Ca2? decay compared to healthy controls,
consistent with the decrease of systolic and diastolic
function typical of heart failure [199, 200].
Fabry disease
Fabry disease is a rare X-linked metabolic disorder char-
acterized by deficiency of the enzyme a-galactosidase and
encoded by the GLA gene, causing progressive lysosomal
accumulation of globotriaosylceramide (GL-3) in the kid-
ney, heart, and other tissues throughout the body [201].
In 2013, Kawagoe and colleagues generated hiPSCs
from human fibroblasts of patients affected by Fabry dis-
ease. Electron microscopic analysis indicated that Fabry-
hiPSCs exhibited massive accumulation of membranous
cytoplasmic body (MCB) in the lysosomes, which is typi-
cal of Fabry disease, and they could not be easily
differentiated into cardiomyocytes due to the continuous
damages of the intracellular architecture [201]. By contrast,
in a study by Itier and colleagues, hiPSCs generated from
Fabry patients were successfully differentiated toward the
cardiac fate [202]. Importantly, GL-3 resulted accumulated
over time in the lysosomes of these cardiomyocytes and
typical features of Fabry disease were observed (displace-
ment of cardiac myofibrils to the periphery of the cells,
focal areas of myofibrillar lysis, and myofilament degra-
dation with troponin I degradation products). Furthermore,
this in vitro model also demonstrated that substrate
reduction therapy via inhibition of the enzyme glucosyl-
ceramide synthase (GCS) prevented accumulation of GL-3
in hiPSC-CMs.
Since enzyme replacement therapy (ERT) is currently
the only efficient therapy in Fabry disease, there is a need
to identify pathogenetic biomarkers and therapeutic targets
in ERT-treated patients. On this note, Chien and colleagues
recently constructed an iPSC-based disease model from
patients carrying a GLA mutation (IVS4?919 G[A)
responsible for Fabry disease [203] and demonstrated for
the first time that Interleukin-18 (IL-18), a pro-hyper-
trophic inflammatory cytokine involved in several cardiac
diseases, is involved in the pathogenesis of the disease
[204]. Interestingly, these findings suggest that targeting
IL-18 might be a potential adjunctive therapy combined
with ERT in Fabry patients with the IVS4?919 G[A
mutation [204].
Diabetes-induced cardiomyopathy
Patients affected by type-2 diabetes mellitus (T2DM) can
be more easily affected by coronary artery disease, a
condition that can progress to dilated cardiomyopathy and
heart failure [205, 206]. Importantly, T2DM alters the
cardiomyocyte-metabolic profile [207], which results in the
decrease of ATP production followed by reduction of
myocardial efficiency and accumulation of toxic lipid
metabolites [208]. Furthermore, mitochondrial dysfunction
and ROS production activate ROS-sensitive proteases that
cleave myofilament proteins [209], whereas proteolytic
damage and inadequate protein production cause sarcom-
ere disorganization [66].
In 2014, Drawnel and colleagues investigated diabetes-
dependent changes in cardiomyocyte functionality by
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developing an in vitro DCM model using T2DM-hiPSCs
[66]. In such study, the diabetes-induced cardiomyopathy
phenotype was recapitulated in hiPSCs-CMs after exposure
of the cells to a diabetic environment, consisting on per-
sistent insulin signaling in the absence of glucose, to force
the adaptation to fatty acids. Treated cells showed disor-
ganized sarcomeres, altered Ca2? transients, cellular
hypertrophy, lipid intracellular accumulation, oxidative
stress, and decreased expression of genes controlling pro-
tein production. Moreover, treated cardiomyocytes were
exposed to a library of 480 compounds to identify small
molecules that could prevent the development of the dia-
betic phenotype. Interestingly, small molecules involved in
Ca2? homeostasis and Na? and K? channel blockers, as
well as multikinase inhibitors and protein synthesis inhi-
bitors were identified as candidate protective drugs from
diabetes-induced cardiomyopathy [66].
Non-cardiovascular diseases with cardiac traits
Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is an X-linked
genetic disease caused by frameshift mutations in the
dystrophin gene, which results in the translation of a
truncated and non-functional dystrophin protein [210].
Dystrophin is part of the dystrophin–glycoprotein complex,
which connects the actin cytoskeleton to the extracellular
matrix, providing cellular stability [211]. In patients
affected by DMD, myocytes are particularly sensitive to
mechanical stress and rupture, which contributes to muscle
degeneration, fibrotic tissue deposition, and premature
death. Patients affected by DMD display diastolic dys-
function, arrhythmias, and cardiomyopathy [212].
In 2015, Lin and colleagues generated hiPSC-CMs from
healthy individuals and patients affected by DMD. Nota-
bly, DMD-hiPSC-CMs recapitulated key features of the
disease phenotype (dystrophin deficiency, cytosolic Ca2?
overload, mitochondrial damage, and cell apoptosis).
Moreover, this study showed that the membrane sealant
Poloxamer 188 can suppress the cytosolic Ca2? overload,
repress Caspase-3 activation, and decrease cardiomyocyte
apoptosis in DMD-hiPSC-CMs [213].
To detect cell structure- and contractile function-prop-
erties typical of the DMD disease phenotype,
Macadangdang and colleagues cultured healthy and dis-
eased DCM-hiPSC-CMs on a novel engineered platform
termed ‘‘anisotropically nanofabricated substrata’’ [212].
This nanopatterned model consisted of 800 nm parallel
arrays of grooves and ridges for mimicking the structure of
the myocardial extracellular matrix. Although structural
differences between healthy and DMD-hiPSC-CMs were
masked on the conventional flat substrates, DMD-hiPSC-
CMs cultured on the nanotopographic substrate displayed
lower structural and functional responses to the underlying
nanotopography when compared to healthy cardiomy-
ocytes, probably due to a lower level of actin cytoskeleton
turnover, suggesting that DMD-hiPSC-CMs are less
adaptable to changes in their extracellular environment
[212].
Familial transthyretin amyloidosis
Familial transthyretin amyloidosis (ATTR) is a lethal,
autosomal-dominant disorder caused by single base-pair
mutations in the TTR gene encoding for the 55 kDa
transport protein transthyretin secreted by the liver [214].
However, the liver is not a clinically relevant site of
amyloid deposition in vivo, whilst the brain and the heart
are the major organs that are affected, suggesting a need
for a multi-lineage model capable of recapitulating the
complexity of ATTR disease phenotype in vitro. To
model the three major tissues involved in this disease,
Leung et al. generated ATTR patient-specific hiPSCs and
differentiated them into hepatocytes, neurons, and car-
diomyocytes [215]. hiPSC-derived neurons and
cardiomyocytes displayed oxidative stress and increased
cell death when exposed to TTR produced by patient-
matched hiPSC-derived hepatocytes. Moreover, small
molecule stabilizers of TTR, such as diflunisal and
flufenamic acid, confirmed their efficacy in this model.
Collectively, this study recapitulated key aspects of the
ATTR disease phenotype in vitro, demonstrating that
hiPSCs can also model disorders in which multiple tissues
are affected [215].
Conclusions
hPSC-CMs already have diverse applications, ranging from
studying human heart development to cardiac disease
modeling and drug testing. They are perceived as having
significant value. However, before the technology becomes
widely accepted in the cardiovascular disease field as
clinically relevant and predictive in human drug testing
applications, some crucial hurdles need to be addressed.
First, directed differentiation of hPSCs in vitro to specific
cardiomyocyte subtypes is still somewhat of a challenge,
even though a number of studies have reported specific
derivation of atrial-, ventricular-, and pacemaker-like cells.
This is due to the limited understanding of later cardiac
development in vivo, sometimes continued use of poorly
defined (serum-containing) or uncontrolled (such as growth
factors not optimally titrated) differentiation culture con-
ditions in vitro. Nevertheless, increased knowledge of heart
formation together with deeper understanding of signaling
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pathways involved in cardiomyocyte development is now
leading to the establishment of more defined methods for
differentiation that are applicable over multiple hPSC lines
and enrich for specific cardiomyocyte subtypes
[29, 58, 65, 216–219]. Second, in most standard culture
conditions, hPSC-CMs do not display all of the morpho-
logical and functional characteristics of adult
cardiomyocytes. This needs to be taken into account when
studying late-onset cardiovascular diseases but also
mechanisms that are based on the highly specialized con-
traction machinery or gene splicing variants only expressed
postnatally. Of note in this context, recent strategies based
on biochemical, molecular, or bioengineering approaches
[220, 221] have been developed to enhance hPSC-CM
maturation. In the biochemical approaches, hormones or
adrenergic agonists have been added to improve car-
diomyocyte functionality [222]. In the molecular
approaches, cardiac ion channels (such as IK1) and micro-
RNAs have been overexpressed to improve
electrophysiology and Ca2? handling
[57, 72, 73, 223–225]. In the bioengineering approaches,
controlled substrate stiffness, topography, and electrical/
mechanical conditioning, as well as integrated systems to
deliver nutrients, such as microsystems and bioreactors, all
improved sarcomeric organization and contractility [220].
In this regard, additional signatures based on gene
expression switches during heart development have been
used to track the maturation status of hiPSC-CMs [226].
Among these, inactivation of the fetal TNNI1 isoform and
its replacement by the adult TNNI3 isoform have proven
valuable in quantifying cardiomyocyte maturation in dif-
ferentiated cultures [46, 226]. Third, the 2D
microenvironment in which hPSC-CMs are cultured does
not entirely recapitulate the complex dynamics and prop-
erties of the human heart [34]. hPSC-CMs can be cultured
in 3D either on scaffolds that serve as a platform for cell
attachment [227], or in scaffold-free systems in which cells
self-organize into structures termed ‘‘cardiac microtissues’’
[228–230]. In this context, several microphysiological
systems that use hiPSC-CMs have been developed for drug
screening and cardiotoxicity testing [34]. Finally, it is
becoming clear that including non-cardiomyocyte cell
types to generate multicellular in vitro tissues is essential to
advance current disease models, which primarily focus on
monotypic cultures of cardiomyocytes, neglecting other
cellular components of the myocardium. Endothelial cells,
cardiac fibroblasts and smooth muscle cells all provide
essential contributions to myocardial structure and function
and also play crucial roles in drug-induced cardiovascular
toxicity [229, 231]. Providing a system that more closely
approximates human heart biology and physiology will
allow the generation of more efficient and predictive
platforms for modeling complex diseases, for the
development of new drug candidates, and also for rescuing
(or rehabilitating) molecules that have been withdrawn
because of negative outcomes in toxicity assays.
In conclusion, the past few years have witnessed
remarkable advances in developmental biology, cell
reprogramming, tissue engineering techniques, and in the
establishment of innovative molecular assays. Patient-
specific hiPSC-CMs and tissue models hold the potential to
further advance basic research, on one hand, and person-
alized and regenerative medicine, on the other hand.
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Sendón JL, Jalife J, Delpón E, Tamargo J (2017) Tbx20 controls
the expression of the KCNH2 gene and of hERG channels. Proc
Natl Acad Sci USA 114:E416–E425. doi:10.1073/pnas.
1612383114
99. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL,
Moss AJ, Towbin JA, Keating MT (1995) SCN5A mutations
associated with an inherited cardiac arrhythmia, long QT syn-
drome. Cell 80:805–811. doi:10.1016/0092-8674(95)90359-3
100. Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NBE, Tan TH, Wong
KY, Shim W, Wong P, Cook SA, Liew R (2013) Modeling type
3 long QT syndrome with cardiomyocytes derived from patient-
specific induced pluripotent stem cells. Int J Cardiol
168:5277–5286. doi:10.1016/j.ijcard.2013.08.015
101. Terrenoire C, Wang K, Chan Tung KW, Chung WK, Pass RH,
Lu JT, Jean J-C, Omari A, Sampson KJ, Kotton DN, Keller G,
Kass RS (2012) Induced pluripotent stem cells used to reveal
drug actions in a long QT syndrome family with complex
genetics. J Gen Physiol 141:61–72. doi:10.1085/jgp.201210899
102. Fatima A, Kaifeng S, Dittmann S, Xu G, Gupta MK, Linke M,
Zechner U, Nguemo F, Milting H, Farr M, Hescheler J, Šarić T
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133. Devalla HD, Gélinas R, Aburawi EH, Beqqali A, Goyette P,
Freund C, Chaix M-A, Tadros R, Jiang H, Le Béchec A,
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